Medicamen Biotech Limited (MEDICAMEQ.BO)
INR 440.85
(6.72%)
INR 440.85
(6.72%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 109.31 Million INR | -26.36% |
| 2022 | 148.44 Million INR | -0.36% |
| 2021 | 148.97 Million INR | 22.82% |
| 2020 | 121.29 Million INR | -8.74% |
| 2019 | 132.91 Million INR | 10.52% |
| 2018 | 120.25 Million INR | 18.92% |
| 2017 | 101.12 Million INR | 95.98% |
| 2016 | 51.6 Million INR | 973.02% |
| 2015 | 4.8 Million INR | 9.14% |
| 2014 | 4.4 Million INR | 367.85% |
| 2013 | 941.82 Thousand INR | 101.91% |
| 2012 | -49.27 Million INR | -497.63% |
| 2011 | -8.24 Million INR | -129.69% |
| 2010 | 27.76 Million INR | -30.16% |
| 2009 | 39.76 Million INR | 188.69% |
| 2008 | 13.77 Million INR | -8.79% |
| 2007 | 15.1 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 13.51 Million INR | -36.5% |
| 2023 FY | 109.31 Million INR | -26.36% |
| 2023 Q1 | 41.77 Million INR | 7.54% |
| 2023 Q2 | 14.76 Million INR | -64.65% |
| 2023 Q3 | 20.29 Million INR | 37.46% |
| 2023 Q4 | 21.27 Million INR | 4.82% |
| 2022 FY | 148.44 Million INR | -0.36% |
| 2022 Q4 | 38.84 Million INR | 3.03% |
| 2022 Q3 | 37.7 Million INR | 4.61% |
| 2022 Q2 | 36.04 Million INR | 0.51% |
| 2022 Q1 | 35.85 Million INR | 30.61% |
| 2021 Q2 | 42.21 Million INR | 1.7% |
| 2021 FY | 148.97 Million INR | 22.82% |
| 2021 Q3 | 37.78 Million INR | -10.5% |
| 2021 Q1 | 41.51 Million INR | 13.83% |
| 2021 Q4 | 27.45 Million INR | -27.34% |
| 2020 Q1 | 22.44 Million INR | -10.0% |
| 2020 Q2 | 32.23 Million INR | 43.65% |
| 2020 Q3 | 30.14 Million INR | -6.48% |
| 2020 Q4 | 36.46 Million INR | 20.97% |
| 2020 FY | 121.29 Million INR | -8.74% |
| 2019 FY | 132.91 Million INR | 10.52% |
| 2019 Q2 | 38.37 Million INR | 16.94% |
| 2019 Q3 | 36.79 Million INR | -4.11% |
| 2019 Q1 | 32.81 Million INR | 15.55% |
| 2019 Q4 | 24.93 Million INR | -32.23% |
| 2018 Q4 | 28.39 Million INR | 18.1% |
| 2018 Q2 | 35.59 Million INR | 10.48% |
| 2018 FY | 120.25 Million INR | 18.92% |
| 2018 Q1 | 32.22 Million INR | 73.01% |
| 2018 Q3 | 24.04 Million INR | -32.45% |
| 2017 Q2 | 26.78 Million INR | 6.89% |
| 2017 Q3 | 28.4 Million INR | 6.02% |
| 2017 Q4 | 18.62 Million INR | -34.42% |
| 2017 FY | 101.12 Million INR | 95.98% |
| 2017 Q1 | 25.06 Million INR | 117.81% |
| 2016 Q1 | 11.32 Million INR | -37.69% |
| 2016 FY | 51.6 Million INR | 973.02% |
| 2016 Q4 | 11.5 Million INR | -33.44% |
| 2016 Q2 | 11.48 Million INR | 1.43% |
| 2016 Q3 | 17.28 Million INR | 50.52% |
| 2015 FY | 4.8 Million INR | 9.14% |
| 2015 Q3 | -14.59 Million INR | -515.78% |
| 2015 Q4 | 18.17 Million INR | 224.52% |
| 2015 Q2 | 3.51 Million INR | 254.01% |
| 2015 Q1 | -2.27 Million INR | -4007.88% |
| 2014 Q4 | 58.31 Thousand INR | 101.58% |
| 2014 Q1 | 3.03 Million INR | 168.38% |
| 2014 Q2 | 5 Million INR | 64.88% |
| 2014 FY | 4.4 Million INR | 367.85% |
| 2014 Q3 | -3.69 Million INR | -173.76% |
| 2013 Q3 | -4.27 Million INR | -183.69% |
| 2013 Q2 | 5.1 Million INR | 12.32% |
| 2013 Q4 | -4.43 Million INR | -3.84% |
| 2013 FY | 941.82 Thousand INR | 101.91% |
| 2013 Q1 | 4.54 Million INR | 135.91% |
| 2012 Q2 | -12.06 Million INR | -53.15% |
| 2012 Q4 | -12.66 Million INR | 24.02% |
| 2012 FY | -49.27 Million INR | -497.63% |
| 2012 Q1 | -7.88 Million INR | -132.48% |
| 2012 Q3 | -16.66 Million INR | -38.1% |
| 2011 Q4 | 24.25 Million INR | 354.94% |
| 2011 FY | -8.24 Million INR | -129.69% |
| 2011 Q2 | -22.98 Million INR | 0.0% |
| 2011 Q3 | -9.51 Million INR | 58.61% |
| 2010 FY | 27.76 Million INR | -30.16% |
| 2009 FY | 39.76 Million INR | 188.69% |
| 2008 FY | 13.77 Million INR | -8.79% |
| 2008 Q4 | -6.03 Million INR | 0.0% |
| 2007 FY | 15.1 Million INR | 0.0% |
| 2007 Q4 | 6.07 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bal Pharma Limited | 73.92 Million INR | -47.872% |
| Achyut Healthcare Limited | 5.73 Million INR | -1807.013% |
| Alkem Laboratories Limited | 17.95 Billion INR | 99.391% |
| Divi's Laboratories Limited | 16 Billion INR | 99.317% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 100.728% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 97.679% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 155.407% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.429% |
| Medico Remedies Limited | 82.9 Million INR | -31.843% |
| Megasoft Limited | -127.46 Million INR | 185.756% |
| Procter & Gamble Health Limited | 2 Billion INR | 94.561% |
| Piramal Pharma Limited | 178.2 Million INR | 38.659% |
| Sequent Scientific Limited | -358.69 Million INR | 130.475% |
| Sigachi Industries Limited | 571.8 Million INR | 80.883% |
| Ajanta Pharma Limited | 8.16 Billion INR | 98.661% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.886% |
| Brooks Laboratories Limited | -195.91 Million INR | 155.793% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 94.96% |
| Themis Medicare Limited | 435.23 Million INR | 74.885% |
| Unichem Laboratories Limited | -704.74 Million INR | 115.511% |
| Hester Biosciences Limited | 188.89 Million INR | 42.13% |
| Venus Remedies Limited | 284.9 Million INR | 61.633% |
| Indoco Remedies Limited | 984.6 Million INR | 88.898% |
| Ind-Swift Limited | 142.31 Million INR | 23.19% |
| Aarti Drugs Limited | 1.71 Billion INR | 93.623% |
| Alpa Laboratories Limited | 167.76 Million INR | 34.843% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 93.232% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.804% |
| Granules India Limited | 4.05 Billion INR | 97.303% |
| Gufic Biosciences Limited | 861.35 Million INR | 87.31% |
| Hikal Limited | 696.02 Million INR | 84.295% |
| RPG Life Sciences Limited | 876.6 Million INR | 87.53% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 96.36% |
| Windlas Biotech Limited | 581.87 Million INR | 81.214% |
| ZIM Laboratories Limited | 172.46 Million INR | 36.619% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 97.403% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 91.869% |
| Jubilant Pharmova Limited | 771 Million INR | 85.822% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.655% |
| Bajaj HealthCare Limited | -837.93 Million INR | 113.045% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -1441.314% |
| Ipca Laboratories Limited | 5.47 Billion INR | 98.003% |
| Lasa Supergenerics Limited | -217.3 Million INR | 150.302% |
| Laurus Labs Limited | 1.6 Billion INR | 93.192% |
| NATCO Pharma Limited | 13.88 Billion INR | 99.213% |
| Nectar Lifesciences Limited | 49.95 Million INR | -118.839% |
| Shilpa Medicare Limited | 318.74 Million INR | 65.706% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 101.927% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 99.34% |
| Wanbury Limited | 559.56 Million INR | 80.465% |
| Wockhardt Limited | -4.63 Billion INR | 102.361% |
| Strides Pharma Science Limited | -706.14 Million INR | 115.48% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 85.513% |
| Suven Life Sciences Limited | -1.05 Billion INR | 110.403% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 75.694% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 98.225% |
| Eris Lifesciences Limited | 3.91 Billion INR | 97.211% |
| Lupin Limited | 19.14 Billion INR | 99.429% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 102.823% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 56.819% |
| Valiant Laboratories Limited | 3.19 Million INR | -3320.213% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.717% |
| FDC Limited | 3.05 Billion INR | 96.419% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 98.022% |
| Novartis India Limited | 851.9 Million INR | 87.169% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 51.338% |
| Neuland Laboratories Limited | 3 Billion INR | 96.357% |
| Morepen Laboratories Limited | 961.59 Million INR | 88.632% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 25.137% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 220.496% |